Quantum BioPharma Ltd C.QNTM

RE:RE:RE:RE:Look At The Facts They Speak Volumes

[Mil_Man54]

Kinda glossed over everything else.. eh Rosenberg....what...couldn't find an article saying it's OK to mislead investors and get successfully sued...or one that says an RS of 201:1 is a good thing....how about one that says dilution of shares as a primary and ongoing source of funding is a solid business strategy....or how about one that says 2 failed ventures and a continued strategy of hype with no follow through shows they have some solid leadership there.....you starting to get the hint yet on why I say you cherry pick your data/facts.....just look at your reply and wait for the light bulb....

DavidRosenberg wrote:

Mil_Man54 wrote: Rosenberg....show me a successful company who in their history that has 2 failed endeavours....that was successfully sued for purposely misleading investors....produced no revenue for 3 years....performed the largest RS in CSE history....is unable to unload a major facilty....and using share dilution as their go to for financing pet projects....

DavidRosenberg wrote:

Walter333 wrote: Look at the facts, past performance history, and all filings over the years.

show me a biotech company with no debt on the balance sheet and with 40,000,000 USD in the bank that has 3 molecules pending the start of clinical trials that have strong IP and that nobody else has 

you can't find much

FSD is undervalued in my opinion that's why i averaged down last time

all stocks carrry risks and im not a professional so dont take my word as advvice to buy sell or hold any security ever!

but for me personally i think FSD has merit if they can prove their drugs work.

Do your own DD dont listen to the bashers or pumpers on this board !!

 

Biotechs at this stage dont need revenues

Biotech Valuation Best Practices | Toptal

Why Biotech Pipeline Valuation Is Different

Biotech firms are not your standard widget manufacturer that you learned to value in your MBA and/or CFA courses. Read on to understand some of the unique traits specific to the industry.

What Revenues?

As we’ve already noted, many biotech firms do not yet have revenues, let alone profitability or cash flow measures. In fact, cash flows prior to approval of a drug will be significantly negative. That means “standard” valuation multiples like EV/EBITDA or P/E are less relevant. There are some alternative multiples like EV/invested R&D, which is essentially a cost-based valuation. The comparative valuation methodology is another popular methodology which utilizes public market comparables or comparable M&A transactions. It is often not applicable because most biotech companies are idiosyncratic, thus rendering comparative analysis of limited use. We will review an alternative valuation method below.

Even for more established biotech companies, their historical revenues are typically idiosyncratic enough that estimates still have to be built up from scratch rather than relying on past intra-company experience/data or even from other, comparable companies as guide rails for projections. In other words, the typical approach to projections of extrapolating past trends is pretty much out. For example, see below for the current pipeline of Swiss pharmaceutical research company Idorsia and note the range and variety of both mechanism of action (the process by which the drug produces a pharmacological effect) and target indications (the use of that drug for treating a certain disease).